Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
August 14: number of AUTHORIZED shares raised from 125 million to UNLIMITED
In yesterdays' tweet: IRB established.
The Institutional Review Board reviews and monitors biomedical research involving human subjects (Halberd is conducting clinical trials on Veterans and active duty personel). In accordance with FDA regulations, an IRB has the authority to approve, require modifications (to secure approval), or disapprove research.
Halberd's /Athena's treatment for PTSD is called WatchDawg. Athena coordinates all actions for the military, Halberd the non-military.
the program is being tested right now and is called WatchDawg
Athena also monitors the patient and gives feedback
Athena is adding AI and data collection
LDN+ test results imminent
downgraded to Pink Limited Information
and RNVA is late as well; curious how much they transferred to INQR to work on the Curallo platform
and now they're late filing the annual report!!!
$HALB 0.0084 (NO BRAINER)
News out about CRADA (military contract) to start pilot test for patented LDN+ product, to treat PTSD, depression etc, Multi BILLION market
Also at the moment pilot testing at Mississippi State University on large animals of a (patent pending) nasal spray to treat brain damage. First pilot (on small animals) huge success, most reliable biomarker showed 51% reduction!!!
For both products military contracts expected of $6 million. FDA clinical trials expected to start within 2 months.
https://www.accesswire.com/849919/halberds-patented-drug-ldn-the-subject-of-a-limited-clinical-trial-under-an-innovative-four-company-cooperative-research-and-development-crada-contract
https://www.otcmarkets.com/stock/HALB/news/Halberd-and-Mississippi-State-University-to-Commence-Stage-II-Advanced-TBI-Nasal-Spray-Testing?id=429883
https://www.doi.gov/techtransfer/crada
$HALB 0.0084 (NO BRAINER)
News out about CRADA (military contract) to start pilot test for patented LDN+ product, to treat PTSD, depression etc, Multi BILLION market
Also at the moment pilot testing at Mississippi State University on large animals of a (patent pending) nasal spray to treat brain damage. First pilot (on small animals) huge success, most reliable biomarker showed 51% reduction!!!
For both products military contracts expected of $6 million. FDA clinical trials expected to start within 2 months.
https://www.accesswire.com/849919/halberds-patented-drug-ldn-the-subject-of-a-limited-clinical-trial-under-an-innovative-four-company-cooperative-research-and-development-crada-contract
https://www.otcmarkets.com/stock/HALB/news/Halberd-and-Mississippi-State-University-to-Commence-Stage-II-Advanced-TBI-Nasal-Spray-Testing?id=429883
https://www.doi.gov/techtransfer/crada
What does Athena get in return?
Well, if they're not stupid (they're not) they get at least 50% of all revenue. As you know it is Athena who filed for the two government grants, a total of 6M. They will get it and because of that they guarantee all bills from MSU (nasal spray). Same with LDN+. I did some research and the road to FDA approval for LDN+ is very short. We're waiting for news about both. So far investing in $HALB has turned out very profitable. I took some profits when they "peaked", but now have more than ever, buying the dips.
waiting for news about the 2 gov. contracts
working on the nasal spray to treat brain damage en LDN+
partnered with Athena who pays the R&D bills
Hi Squid, nice to see you're back....
WEST PALM BEACH, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- InnovaQor, Inc. (OTC: INQR) announces that, to date, certain common shareholders have agreed to exchange a total of 40,700,000 common shares for shares of Series E and F Preferred Stock at an exchange value of $0.005 per share of common stock. Each shareholder will receive 50% of the value of common shares exchanged in Series E Preferred Stock and the remaining 50% in Series F Preferred Stock. This reduces the currently issued number of common shares from 244,953,286 to 204,253,286.
https://www.otcmarkets.com/stock/INQR/news/story?e&id=2772886
funding is being spend on building Curallo
but RNVA is still funding Innovaqor
no follow up to the 8-K about RS
very quiet lately
$HALB OS 635M SP 0.009
Something happening (finally):
- signed a funding/revenue sharing agreement with Athena GTX
- together working on 2 military contracts for $6M
- Athena GTX gets more than 50% of its revenue from government contracts
- together developing treatments against PTSD, TBI, pain&anxiety
Today HALB announced a second phase in animal testing at Mississippi State University
https://www.otcmarkets.com/stock/HALB/news/Halberd-and-Mississippi-State-University-to-Commence-Stage-II-Advanced-TBI-Nasal-Spray-Testing?id=429883
$HALB OS 635M SP 0.009
Something happening (finally):
- signed a funding/revenue sharing agreement with Athena GTX
- together working on 2 military contracts for $6M
- Athena GTX gets more than 50% of its revenue from government contracts
- together developing treatments against PTSD, TBI, pain&anxiety
Today HALB announced a second phase in animal testing at Mississippi State University
https://www.otcmarkets.com/stock/HALB/news/Halberd-and-Mississippi-State-University-to-Commence-Stage-II-Advanced-TBI-Nasal-Spray-Testing?id=429883
CHECK Twitter:
Halberd Corporation
@HalberdC
Stay tuned for two significant announcements from $HALB early this week!
1:44 PM · Jan 8, 2024
·
224 Views
You have to go back to May '23 interview to know what's coming. Everybody thought it was more bluff, but seems he nailed it. If so: boom!
I have a very good feeling going into 2024. It has been quiet for a long time, dealing with potential partners, but I’m sure Halberd will rock.
talks with AthenaGTX take longer than expected
quarterly report, nothing new, no subsequent events
company still OTC Current information
financial report filed
CURALLO is on youtube. Also a short version on the Innovaqor/curallo website. You have to register first to view the full version. IT LOOKS GREAT!
$INQR Innovaqor Inc SP 0.0037 Float 158M MC 900K
INQR is developing a Communication Platform for Healthcare Professionals:
- the communication network is called CURALLO
- fully funded ($1 million in 2023, $2.5 million last 2 years) by former parent company
- company has audited fins and is fully SEC reporting
- part of the platform is a Recruitment platform for employers (hospitals, clinics etc), think LinkedIn
- revenue from subscription fees, talent search etc.
This stock will explode soon. I expect updates about partners and multi-million dollar funding. Take a first look:
insert-text-here
https://www.otcmarkets.com/stock/INQR/security
$INQR Innovaqor Inc SP 0.0037 Float 158M MC 900K
INQR is developing a Communication Platform for Healthcare Professionals:
- the communication network is called CURALLO
- fully funded ($1 million in 2023, $2.5 million last 2 years) by former parent company
- company has audited fins and is fully SEC reporting
- part of the platform is a Recruitment platform for employers (hospitals, clinics etc), think LinkedIn
- revenue from subscription fees, talent search etc.
This stock will explode soon. I expect updates about partners and multi-million dollar funding. Take a first look:
insert-text-here
https://www.otcmarkets.com/stock/INQR/security
$INQR 0.0027 MC 0.6M
INNOVAQOR, INC. CREATES PREFERRED STOCK; CONSIDERS LAUNCHING EXCHANGE OFFER TO COMMON SHAREHOLDERS
November 27, 2023 09:00 ET
| Source: InnovaQor, Inc.
WEST PALM BEACH, Fla., Nov. 27, 2023 (GLOBE NEWSWIRE) -- InnovaQor, Inc. (OTC: INQR) authorized two new series of preferred stock, the Series E Mandatory Convertible Preferred Stock and the Series F Mandatory Convertible Preferred Stock, by filing certificates of designation with the Secretary of State of the State of Nevada on November 22, 2023. The Company authorized the two series of preferred stock in contemplation of a potential exchange offer to be made to its common shareholders.
The Company is considering offering common shareholders the opportunity to exchange common shares for a stated value of Series E and Series F Preferred Stock. The value of common shares exchanged would be divided equally between Series E and Series F Preferred Stock. The Series E Preferred Stock has a mandatory conversion date of December 31, 2026 and the Series F Preferred Stock has a mandatory conversion date of December 31, 2027. The stated value each series of preferred stock initially is $100, and increases by $20 upon each anniversary of issuance.
As an example, as currently contemplated, if a common shareholder exchanges $1,000 of common shares they will receive $500 of Series E Preferred Stock and $500 of Series F Preferred Stock.
The $500 of Series E Preferred Stock shall have a stated value of (i) $600 from the first anniversary of the original issue date until the day before the second anniversary of the Original Issue Date; and (ii) $700 from and after the second anniversary of the original issue date until the day before the third anniversary of the original issue date; and (iii) $800 on the third anniversary until the mandatory conversion date at which time the total stated value of the Series E Preferred Stock ($800.00) would automatically convert to common stock of the Company at the average closing price of the Common Stock on the 10 Trading Days immediately prior to the mandatory conversion date.
The $500 of Series F Preferred Stock shall have a stated value of (i) $600 from the first anniversary of the original issue date until the day before the second anniversary of the Original Issue Date; and (ii) $700 from and after the second anniversary of the original issue date until the day before the third anniversary of the original issue date; and (iii) $800 from and after the third anniversary of the original issue date until the day before the fourth anniversary of the original issue date; and (iv) $900 on the fourth anniversary until the mandatory conversion date at which time the total stated value of the Series F Preferred Stock ($900.00) would automatically convert to common stock of the Company at the average closing price of the Common Stock on the 10 Trading Days immediately prior to the mandatory conversion date.
“We believe an exchange offer is a viable and exciting alternative to completing a reverse split of our common stock in an effort to make our Company more attractive to new investors” said Darrell Peterson, CEO of InnovaQor, Inc. “Our Company is entering a phase where new investors are necessary to help us create a significantly more valuable Company. If successful, an exchange offer would create more opportunity to our current shareholders than other methods of restructuring our current capitalization to attract investment.”
The terms and timing of an exchange offer are subject to final approval by the Board of Directors of the Company and market conditions.
$INQR $0.0027 MC 0.6M
INNOVAQOR, INC. CREATES PREFERRED STOCK; CONSIDERS LAUNCHING EXCHANGE OFFER TO COMMON SHAREHOLDERS
November 27, 2023 09:00 ET
| Source: InnovaQor, Inc.
WEST PALM BEACH, Fla., Nov. 27, 2023 (GLOBE NEWSWIRE) -- InnovaQor, Inc. (OTC: INQR) authorized two new series of preferred stock, the Series E Mandatory Convertible Preferred Stock and the Series F Mandatory Convertible Preferred Stock, by filing certificates of designation with the Secretary of State of the State of Nevada on November 22, 2023. The Company authorized the two series of preferred stock in contemplation of a potential exchange offer to be made to its common shareholders.
The Company is considering offering common shareholders the opportunity to exchange common shares for a stated value of Series E and Series F Preferred Stock. The value of common shares exchanged would be divided equally between Series E and Series F Preferred Stock. The Series E Preferred Stock has a mandatory conversion date of December 31, 2026 and the Series F Preferred Stock has a mandatory conversion date of December 31, 2027. The stated value each series of preferred stock initially is $100, and increases by $20 upon each anniversary of issuance.
As an example, as currently contemplated, if a common shareholder exchanges $1,000 of common shares they will receive $500 of Series E Preferred Stock and $500 of Series F Preferred Stock.
The $500 of Series E Preferred Stock shall have a stated value of (i) $600 from the first anniversary of the original issue date until the day before the second anniversary of the Original Issue Date; and (ii) $700 from and after the second anniversary of the original issue date until the day before the third anniversary of the original issue date; and (iii) $800 on the third anniversary until the mandatory conversion date at which time the total stated value of the Series E Preferred Stock ($800.00) would automatically convert to common stock of the Company at the average closing price of the Common Stock on the 10 Trading Days immediately prior to the mandatory conversion date.
The $500 of Series F Preferred Stock shall have a stated value of (i) $600 from the first anniversary of the original issue date until the day before the second anniversary of the Original Issue Date; and (ii) $700 from and after the second anniversary of the original issue date until the day before the third anniversary of the original issue date; and (iii) $800 from and after the third anniversary of the original issue date until the day before the fourth anniversary of the original issue date; and (iv) $900 on the fourth anniversary until the mandatory conversion date at which time the total stated value of the Series F Preferred Stock ($900.00) would automatically convert to common stock of the Company at the average closing price of the Common Stock on the 10 Trading Days immediately prior to the mandatory conversion date.
“We believe an exchange offer is a viable and exciting alternative to completing a reverse split of our common stock in an effort to make our Company more attractive to new investors” said Darrell Peterson, CEO of InnovaQor, Inc. “Our Company is entering a phase where new investors are necessary to help us create a significantly more valuable Company. If successful, an exchange offer would create more opportunity to our current shareholders than other methods of restructuring our current capitalization to attract investment.”
The terms and timing of an exchange offer are subject to final approval by the Board of Directors of the Company and market conditions.
INNOVAQOR, INC. CREATES PREFERRED STOCK; CONSIDERS LAUNCHING EXCHANGE OFFER TO COMMON SHAREHOLDERS
November 27, 2023 09:00 ET
| Source: InnovaQor, Inc.
WEST PALM BEACH, Fla., Nov. 27, 2023 (GLOBE NEWSWIRE) -- InnovaQor, Inc. (OTC: INQR) authorized two new series of preferred stock, the Series E Mandatory Convertible Preferred Stock and the Series F Mandatory Convertible Preferred Stock, by filing certificates of designation with the Secretary of State of the State of Nevada on November 22, 2023. The Company authorized the two series of preferred stock in contemplation of a potential exchange offer to be made to its common shareholders.
The Company is considering offering common shareholders the opportunity to exchange common shares for a stated value of Series E and Series F Preferred Stock. The value of common shares exchanged would be divided equally between Series E and Series F Preferred Stock. The Series E Preferred Stock has a mandatory conversion date of December 31, 2026 and the Series F Preferred Stock has a mandatory conversion date of December 31, 2027. The stated value each series of preferred stock initially is $100, and increases by $20 upon each anniversary of issuance.
As an example, as currently contemplated, if a common shareholder exchanges $1,000 of common shares they will receive $500 of Series E Preferred Stock and $500 of Series F Preferred Stock.
The $500 of Series E Preferred Stock shall have a stated value of (i) $600 from the first anniversary of the original issue date until the day before the second anniversary of the Original Issue Date; and (ii) $700 from and after the second anniversary of the original issue date until the day before the third anniversary of the original issue date; and (iii) $800 on the third anniversary until the mandatory conversion date at which time the total stated value of the Series E Preferred Stock ($800.00) would automatically convert to common stock of the Company at the average closing price of the Common Stock on the 10 Trading Days immediately prior to the mandatory conversion date.
The $500 of Series F Preferred Stock shall have a stated value of (i) $600 from the first anniversary of the original issue date until the day before the second anniversary of the Original Issue Date; and (ii) $700 from and after the second anniversary of the original issue date until the day before the third anniversary of the original issue date; and (iii) $800 from and after the third anniversary of the original issue date until the day before the fourth anniversary of the original issue date; and (iv) $900 on the fourth anniversary until the mandatory conversion date at which time the total stated value of the Series F Preferred Stock ($900.00) would automatically convert to common stock of the Company at the average closing price of the Common Stock on the 10 Trading Days immediately prior to the mandatory conversion date.
“We believe an exchange offer is a viable and exciting alternative to completing a reverse split of our common stock in an effort to make our Company more attractive to new investors” said Darrell Peterson, CEO of InnovaQor, Inc. “Our Company is entering a phase where new investors are necessary to help us create a significantly more valuable Company. If successful, an exchange offer would create more opportunity to our current shareholders than other methods of restructuring our current capitalization to attract investment.”
The terms and timing of an exchange offer are subject to final approval by the Board of Directors of the Company and market conditions.
News today November 27th 2023:
InnovaQor, Inc. (INQR) authorizes two new series of preferred stock, Series E and Series F, for potential exchange offer to common shareholders. The Series E Mandatory Convertible Preferred Stock has a mandatory conversion date of December 31, 2026, and the Series F Mandatory Convertible Preferred Stock has a mandatory conversion date of December 31, 2027. The stated value of each series of preferred stock initially is $100, increasing by $20 upon each anniversary of issuance. The exchange offer is being considered as an alternative to completing a reverse split of common stock to attract new investors. The terms and timing of the exchange offer are subject to final approval by the Board of Directors and market conditions.
This is what I wrote a while ago (see Intro) about Curallo:
InnovaQor is a kind of a pioneer in the domain of creating a social platform for physicians, creating a networking, knowledge sharing, and hiring mechanism along the lines of LinkedIn. There is a global shortfall of 4.3 million doctors, nurses, and other healthcare professionals. Through its platform Curallo.com, INQR primarily targets physician groups, facilities and associations trying to acquire advocacy through the larger governing boards with a member-exclusive discount.
The revenue streams of this social media platform would include freemium, premium subscription fees, sponsorship, talent search per individual/ facility, and so on. As LinkedIn has shown, there is a need for additional access, knowledge, and connectivity, which comes with a monthly premium access fee. In fact, LinkedIn’s data indicates that individuals are willing to spend $30, while corporations are willing to pay $60 for such services which means INQR definitely can earn strong revenues from its niche.
The Talent Search Subscription Program (TSSP) is anticipated to upend the market by utilizing AI for matchmaking based on user profile optimization. The TSSP feature on LinkedIn generates 65% of the company's revenue, displacing market leaders like Monster and Indeed. With INQR/Curallo employing an industry-specific model, TSSP is a boon for healthcare professionals, especially in todays hiring market. Large pharma would find the platform to be alluring for advertising with an engaged industry audience as well. Thus, this new platform could be a huge revenue catalyst for INQR.
From what I heard the curallo MVP is complete. The outside funding that INQR needs is tied to the MVP. Not only does INQR need 2.5 million dollar to repay former parent Rennova, but they also need cash to further develop the healthcare modules. Before this year ends INQR has to repay RNVA's promissory note receivable and therefore I expect news very soon.